GlaxoSmithKline Pharma witnesses slowdown in sales during Q1FY21

Despite the initial disruptions to its supply chain due to the lockdown the company smoothly managed its supply chain operation.

Jun 04, 2020 04:06 IST India Infoline News Service

GlaxoSmithKline Pharmaceuticals Limited informed the exchanges Thursday that it has seen a slowdown in sales across some of its therapeutic areas during Q1FY21 mainly from deferment of vaccination at clinics and slowdown in the non-essential portfolio.

“While the performance and profitability of Q1FY21 may be impacted, we are ramping up our capacities in some of the other therapeutic areas that are essential to our patients in the current circumstances and charting a plan to accelerate growth once the lockdown is eased.”

Despite the initial disruptions to its supply chain due to the lock down the company smoothly managed its supply chain operation. It is currently operating at about 70% of normative manufacturing levels.

The company’s investments into digital transformation have helped it immensely during lockdown to to keep connected with the healthcare professionals (HCPs).

With the relaxation of the lockdown across various zones of the country, we have redeployed our front line as per the guidelines received from the Central/ State/ Municipal authorities and our front lines have been adequately sensitized on the same, company said.

Its head office in Mumbai remains closed during the lock down, and the company has adopted the work from home policy to run the show.

Glaxosmithkline Pharmaceuticals Ltd's ended at Rs1,373.95 up by Rs8.2 or 0.6% from its previous closing of Rs1,365.75 on the BSE.

Related Story